O. S. Golikova
O. S. Golikova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- K. I. Matrenin
Center for Healthcare Quality Assessment and Control
2 shared publications - Vitaliy Vladimirovich Omelyanovskiy
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education
2 shared publications - D. N. Pustovalov
Center for Expertise and Quality Control of Medical Care
1 shared publication - Dmitriy Nikitich Laptev
Endocrinology Research Centre
1 shared publication - E. I. Rumiantseva
Center for Expertise and Quality Control of Medical Care
1 shared publication - Ilya Aleksandrovich Mikhailov
Lomonosov Moscow State University
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 215-223
Estimation of the socio-economic burden of obesity in the Russian Federation
Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 215-223
Open AccessEstimation of the socio-economic burden of obesity in the Russian Federation
Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.
- 26 June 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (2) , 123-138
Cost-effectiveness analysis of screening for type 1 diabetes in children in the Russian Federation
Objective. Cost-effectiveness analysis of screening for type 1 diabetes (T1D) in 6-year-old children by measuring autoantibodies to beta-cell and pancreatic islet antigens followed by longitudinal monitoring of individuals with positive results. Material and methods. The Markov model was used to predict efficacy, direct and indirect costs for three screening scenarios in 6-year-old children after testing for autoantibodies to beta-cell and pancreatic islet antigens: 1) general population; 2) first-degree relatives (FDR); 3) children with autoimmune diseases (AID). For each scenario, two cohorts (screening vs no screening) were simulated over a 50-year time horizon, and incremental cost-effectiveness ratios (ICER) were calculated using quality-adjusted life year (QALY). Results. Across all three scenarios, T1D screening reduced mortality and incidence of long-term complications by preventing diabetic ketoacidosis (DKA) at disease onset and increased QALY. The largest numbers of prevented long-term complications were observed in FDR and AID scenarios: by 18 years for diabetic neuropathy and by 56 years for lower extremity amputation and end-stage chronic kidney disease. In FDR and AID scenarios, ICER fell below 2.3 million rubbles after 7 years. After 16 years, ICER became negative that indicated cost savings alongside higher clinical benefit. In general population, ICER fell below 2.3 million rubbles after 28-year modelling and amounted to 2.287.652.27 RUB per QALY gained. Conclusion. In high-risk groups (FDR and children with AID), T1D screening followed by monitoring of autoantibody-positive individuals is economically justified for Russian healthcare system. In general population, cost-effectiveness emerges only over a long-term horizon (after 28 years). This highlights the need for long-term planning and confirming key clinical effects of screening in routine practice during program scale-up (reduced proportion of DKA at onset and early-disease HbA1c trajectories).
- 26 June 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (2) , 123-138
Cost-effectiveness analysis of screening for type 1 diabetes in children in the Russian Federation
Objective. Cost-effectiveness analysis of screening for type 1 diabetes (T1D) in 6-year-old children by measuring autoantibodies to beta-cell and pancreatic islet antigens followed by longitudinal monitoring of individuals with positive results. Material and methods. The Markov model was used to predict efficacy, direct and indirect costs for three screening scenarios in 6-year-old children after testing for autoantibodies to beta-cell and pancreatic islet antigens: 1) general population; 2) first-degree relatives (FDR); 3) children with autoimmune diseases (AID). For each scenario, two cohorts (screening vs no screening) were simulated over a 50-year time horizon, and incremental cost-effectiveness ratios (ICER) were calculated using quality-adjusted life year (QALY). Results. Across all three scenarios, T1D screening reduced mortality and incidence of long-term complications by preventing diabetic ketoacidosis (DKA) at disease onset and increased QALY. The largest numbers of prevented long-term complications were observed in FDR and AID scenarios: by 18 years for diabetic neuropathy and by 56 years for lower extremity amputation and end-stage chronic kidney disease. In FDR and AID scenarios, ICER fell below 2.3 million rubbles after 7 years. After 16 years, ICER became negative that indicated cost savings alongside higher clinical benefit. In general population, ICER fell below 2.3 million rubbles after 28-year modelling and amounted to 2.287.652.27 RUB per QALY gained. Conclusion. In high-risk groups (FDR and children with AID), T1D screening followed by monitoring of autoantibody-positive individuals is economically justified for Russian healthcare system. In general population, cost-effectiveness emerges only over a long-term horizon (after 28 years). This highlights the need for long-term planning and confirming key clinical effects of screening in routine practice during program scale-up (reduced proportion of DKA at onset and early-disease HbA1c trajectories).
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Drug-drug interactions in clinical practice: a literature review and SWOT analysis
The prevalence of significant drug-drug interactions in clinical practice reaches 27%. Multiple comorbidities and advanced age of patients, prescription of multiple medications and inconsistency in drug prescriptions at various stages of medical care can contribute to these interactions. The negative consequences of drug-drug interactions include adverse reactions, decreased effectiveness of pharmacotherapy, increased incidence and duration of hospitalizations, mortality and higher cost of medical care. Difficult prevention of adverse reactions may be due to insufficient awareness of physicians about tools for identifying drug-drug interactions, no standardized approach to polypharmacy and implementation of restrictive lists of medications in geriatric practice. Searching for data was performed in the Pubmed, Embase, Web of Science databases. Data were analyzed in accordance with methodology of SWOT (strengths-weaknesses-opportunities-threats) analysis: identifying factors of internal and external environment, organization and their division into four categories. Positive aspects of drug-drug interactions include drug synergism that may be considered in case of ineffective monotherapy and prescription of multicomponent pharmacotherapy or fixed combinations of drugs. Awareness about potentially dangerous and contraindicated drug combinations, pharmacogenetic testing, deprescribing, reconciliation of drug prescriptions at all stages of medical care and specialized electronic databases of drug-drug interactions can be used in clinical practice and development of decision-making support systems to improve the effectiveness and safety of pharmacotherapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Drug-drug interactions in clinical practice: a literature review and SWOT analysis
The prevalence of significant drug-drug interactions in clinical practice reaches 27%. Multiple comorbidities and advanced age of patients, prescription of multiple medications and inconsistency in drug prescriptions at various stages of medical care can contribute to these interactions. The negative consequences of drug-drug interactions include adverse reactions, decreased effectiveness of pharmacotherapy, increased incidence and duration of hospitalizations, mortality and higher cost of medical care. Difficult prevention of adverse reactions may be due to insufficient awareness of physicians about tools for identifying drug-drug interactions, no standardized approach to polypharmacy and implementation of restrictive lists of medications in geriatric practice. Searching for data was performed in the Pubmed, Embase, Web of Science databases. Data were analyzed in accordance with methodology of SWOT (strengths-weaknesses-opportunities-threats) analysis: identifying factors of internal and external environment, organization and their division into four categories. Positive aspects of drug-drug interactions include drug synergism that may be considered in case of ineffective monotherapy and prescription of multicomponent pharmacotherapy or fixed combinations of drugs. Awareness about potentially dangerous and contraindicated drug combinations, pharmacogenetic testing, deprescribing, reconciliation of drug prescriptions at all stages of medical care and specialized electronic databases of drug-drug interactions can be used in clinical practice and development of decision-making support systems to improve the effectiveness and safety of pharmacotherapy.